Bias, Spin, and Misreporting: Time for Full Access to Trial Protocols and Results

An-Wen Chan discusses the implications of a new study inPLoS Medicine that suggests that the randomized trial literature is skewed towards reporting favorable results.

[1]  K. Abbasi,et al.  Trial protocols at the BMJ , 2004, BMJ : British Medical Journal.

[2]  D. Altman,et al.  Waiving confidentiality for the greater good , 2006, BMJ : British Medical Journal.

[3]  J. Jureidini,et al.  Clinical trials and drug promotion: Selective reporting of study 329 , 2008 .

[4]  A J Sutton,et al.  Publication and related biases. , 2000, Health technology assessment.

[5]  S. Golder,et al.  The effectiveness and cost-effectiveness of prophylactic removal of wisdom teeth. , 2000, Health technology assessment.

[6]  S. Hahn,et al.  Investigation of within-study selective reporting in clinical research: follow-up of applications submitted to a local research ethics committee. , 2002, Journal of evaluation in clinical practice.

[7]  M. Mitka.  Controversies surround heart drug study: questions about Vytorin and trial sponsors' conduct. , 2008, JAMA.

[8]  R. Kronmal,et al.  Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. , 2008, JAMA.

[9]  Lisa Bero,et al.  Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation , 2008, PLoS medicine.

[10]  B. Beermann,et al.  Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications , 2003, BMJ : British Medical Journal.

[11]  A. Hrõbjartsson,et al.  Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study , 2005, BMJ : British Medical Journal.

[12]  Ida Sim,et al.  Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1) , 2005, BMJ : British Medical Journal.

[13]  Jeffrey M Drazen,et al.  Expression of concern reaffirmed. , 2006, The New England journal of medicine.

[14]  Douglas G Altman,et al.  Epidemiology and reporting of randomised trials published in PubMed journals , 2005, The Lancet.

[15]  C. Hawkey.  Journals should see original protocols for clinical trials , 2001, BMJ : British Medical Journal.

[16]  A. Hrõbjartsson,et al.  Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. , 2004, JAMA.

[17]  K. Dickersin.  How important is publication bias? A synthesis of available data. , 1997, AIDS education and prevention : official publication of the International Society for AIDS Education.

[18]  John Hoey,et al.  Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors , 2005, The Lancet.

[19]  Next Stop, Don't Block the Doors: Opening Up Access to Clinical Trials Results , 2008, PLoS medicine.

[20]  Peter Fonagy,et al.  Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data , 2004, The Lancet.

[21]  E. Turner,et al.  A Taxpayer-Funded Clinical Trials Registry and Results Database , 2004, PLoS medicine.

[22]  Kent Johnson,et al.  The power of the protocol , 2002, The Lancet.

[23]  J. Jureidini,et al.  Industry-Sponsored Ghostwriting in Clinical Trial Reporting: A Case Study , 2008, Accountability in research.

[24]  E. Hemminki.  Study of information submitted by drug companies to licensing authorities. , 1980, British medical journal.

[25]  S. Evans,et al.  Selective reporting in clinical trials: analysis of trial protocols accepted by The Lancet , 2008, The Lancet.

[26]  S. Kleinert,et al.  Protocol review at The Lancet , 1997, The Lancet.

[27]  J. Ioannidis,et al.  Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias , 2008, PloS one.

[28]  Ida Sim,et al.  Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis , 2008, PLoS medicine.

[29]  A. Colevas,et al.  Adverse event reporting in publications compared with sponsor database for cancer clinical trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Djulbegovic,et al.  Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group , 2004, BMJ : British Medical Journal.

[31]  Douglas G Altman,et al.  Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols , 2008, BMJ : British Medical Journal.

[32]  R. Rosenthal,et al.  Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.

[33]  R. Horton,et al.  Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. , 2005, JAMA.

[34]  D. Altman,et al.  Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research , 2004, Canadian Medical Association Journal.

[35]  John Hoey,et al.  Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors , 2005, Canadian Medical Association Journal.

[36]  I. Sim,et al.  Clinical trial registration: transparency is the watchword , 2006, The Lancet.

[37]  P. Lurie,et al.  Sometimes the Silence Can Be Like the Thunder: Access to Pharmaceutical Data at the Fda , 2006 .

[38]  James M Wright,et al.  “Breakthrough” drugs and growth in expenditure on prescription drugs in Canada , 2005, BMJ : British Medical Journal.